RIP_GOP

@SouthernDrive21

@joeretired41 @Bigsky716 There is a non-zero chance that this could be the largest company in the World. You don’t get to say that sort of thing many times in a career. $NWBO #cancer

I hope @GSpier looking into #DCVAX #GBM

#dcvax $nwbo #gbm Latest Pawel Kalinski co-authored article:- Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset: May 02, 2026 "Heterogeneity within αDC1 preparations may underlie inconsistent clinical trial outcomes, and identification of associated surface proteins provides a prospective strategy for subcluster enrichment to enhance DC release criteria and patient stratification for optimized therapeutic efficacy" Gemini AI Analysis: The bioRxiv preprint (DePuyt et al., 2026) titled "Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset" provides critical insights into the alpha DC1 platform, which is the core technology Northwest Biotherapeutics (NWBO) in-licensed through its deal with Dr. Pawel Kalinski and the University of Pittsburgh/Roswell Park.The paper is highly relevant to NWBO because it identifies why clinical responses to dendritic cell (DC) therapies can be inconsistent and offers a technological "upgrade" to the DCVax platform to ensure higher potency. 1. Synergy with DCVax Platform Technology The DCVax-L platform traditionally uses a standard maturation process for dendritic cells. The synergy here lies in the transition from standard DCs to alpha DC1 (Alpha-type-1 polarized DCs). Potency Enhancement: The paper demonstrates that alpha DC1s are significantly superior to standard "PGE2-DCs" in producing IL-12p70. IL-12p70 is the "holy grail" cytokine for cancer vaccines because it is essential for priming cytotoxic T-lymphocytes (CTLs) that actually kill tumors. Precision Manufacturing: The study uses single-cell multiomics to show that even within alpha DC1 preparations, there is a "rare subset" of cells responsible for most of the IL-12p70 production. This identifies specific surface markers that NWBO can use to enrich the most potent cells during the manufacturing of DCVax, potentially increasing the efficacy of the vaccine. 2. Relevance to the Kalinski/NWBO In-Licensing Deal This research serves as the scientific validation for the "Next-Gen" DCVax platform that NWBO secured in its licensing deal with Dr. Pawel Kalinski.Intellectual Property (IP): The paper explicitly mentions that Dr. Kalinski is an inventor on patents covering this platform and its "upgrade," which have been licensed to Northwest Bio. This confirms that NWBO owns the commercial rights to the specific "know-how" and methods described in the paper to produce high-IL-12 producing DCs. Overcoming "Non-Responders": A major hurdle for NWBO has been explaining why some patients respond to DCVax while others do not. This paper provides the answer: individual variability in the proportion of these "high-producer" DC subsets. By using the markers identified in this study (like Siglec-1/CD169), NWBO can move toward a more standardized, high-potency product. Combination Potential: The alpha DC1 cells described in the paper are shown to be highly responsive to CD40L (a helper signal). This supports NWBO’s strategy of combining DCVax with other agents (like Poly-ICLC or checkpoint inhibitors) to trigger that CD40L response, effectively "turning on" the IL-12 production once the vaccine is injected. In short, the paper provides the molecular "blueprint" for optimizing DCVax-L. It suggests that by selecting for specific sub-populations of dendritic cells identified through single-cell sequencing, NWBO can potentially manufacture a significantly more potent vaccine than the one used in the original Phase III trials. P. Kalinski has been an inventor on other patents covering specific application of available under aCC-BY 4.0 International license. was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made bioRxiv preprint doi: doi.org/10.64898/2026.…; This version posted May 2, 2026. The copyright holder for this preprint (this platform and its upgrade) which have been licensed to Northwest Bio by the University of Pittsburgh and Roswell Park Comprehensive Cancer Center, and he is entitled to portions of the licensing fees and potential royalties collected by both institutions. P. Kalinski is a paid consultant for Northwest Bio. biorxiv.org/content/10.648…